Biotest AG
Biotest AG (BIESF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
biesf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Biotest AG (BIESF) measures how much investors pay for each dollar of the company's trailing earnings. BIESF's current PE ratio of N/A is calculated by dividing its stock price of $32.00 by its TTM earnings per share of -$0.64.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 11 fiscal years · Front-end computedMinQ1 · 25%79.8x
MedianQ3 · 75%193.1x
Max
At N/A, BIESF's current P/E is lower than in 0% of its annual fiscal year readings over the past 11 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Biotest AGYou BIESF | $1.6B | N/A | — | -$0.64 |
 Biotage AB (publ) BITGF | $1.2B | 46.23x | +5.0% | $3.55 |
 Opthea Limited CKDXF | $602M | N/A | — | -$0.13 |
 CompuGroup Medical SE & Co. KGaA CMPUY | $1.2B | 33.34x | -24.3% | $0.67 |
 CompuGroup Medical SE & Co. KGaA CMPVF | $1.7B | 52.49x | +19.2% | $0.55 |
 Drägerwerk AG & Co. KGaA DWRKF | $1.8B | N/A | — | — |
 Karo Pharma AB (publ) KARBF | $1.5B | N/A | — | — |
Industry Average 3 peers with valid PE | — | 44.02x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 41.48x | $0.71 | +325.2% | |
2023-12-31 FY2023 | 9.75x | $3.21 | — | |
2022-12-31 FY2022 | — | $-0.80 | — | |
2021-12-31 FY2021 | — | $-1.60 | — | |
2020-12-31 FY2020 | — | $-0.79 | — | |
2019-12-31 FY2019 | — | $-0.12 | — | |
2018-12-31 FY2018 | 5.29x | $4.58 | — | |
2017-12-31 FY2017 | — | $-0.09 | — | |
2016-12-31 FY2016 | — | $-1.16 | — | |
2015-12-31 FY2015 | — | $-2.08 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Biotest AG (BIESF) measures how much investors pay for each dollar of the company's trailing earnings. BIESF's current PE ratio of N/A is calculated by dividing its stock price of $32.00 by its TTM earnings per share of -$0.64.
Frequently asked questions
BIESF pe ratio · 6 questionsBIESF's current PE ratio is N/A as of 2026-06-08, based on a stock price of $32.00 and TTM EPS of -$0.64. Data sourced from Financial Modeling Prep via BIESF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08